Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12–23 months, with a booster dose 12–24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres i...
| Główni autorzy: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Wydane: |
Canadian Medical Association
2017
|
| _version_ | 1826292846591737856 |
|---|---|
| author | Sadarangani, M Sell, T Iro, M Snape, M Voysey, M Finn, A Heath, P Bona, G Esposito, S Diez-Domingo, J Prymula, R Odueyungbo, A Toneatto, D Pollard, A |
| author_facet | Sadarangani, M Sell, T Iro, M Snape, M Voysey, M Finn, A Heath, P Bona, G Esposito, S Diez-Domingo, J Prymula, R Odueyungbo, A Toneatto, D Pollard, A |
| author_sort | Sadarangani, M |
| collection | OXFORD |
| description | BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12–23 months, with a booster dose 12–24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12–24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12–24 months of age received a booster at 4 years of age. Vaccine-naive age-matched toddlers received 2 doses of 4CMenB. Human serum bactericidal antibody titres against reference strains H44/76, 5/99, NZ98/254 and M10713 were evaluated before and after innoculation with 4CMenB vaccine in 4-year-old children. RESULTS: Of 332 children in the study, 123 had previously received 4CMenB and 209 were vaccine-naive controls. Before the booster, the proportions of participants (previously vaccinated groups compared with controls) with hSBA titres of 1:5 or more were as follows: 9%–11% v. 1% (H44/76), 84%–100% v. 4% (5/99), 0%–18% v. 0% (NZ98/254) and 59%–60% v. 60% (M10713). After 1 dose of 4CMenB in previously immunized children, the proportions of participants achieving hSBA titres of 1:5 or more were 100% (H44/76 and 5/99), 70%–100% (NZ98/254) and 90%–100% (M10713). INTERPRETATION: We found that waning of hSBA titres by 4 years of age occurred after 2 doses of 4CMenB vaccine administered at 12–24 months, and doses at 12–24 months have a priming effect on the immune system. A booster may be necessary to maintain hSBA titres of 1:5 or more among those children with increased disease risk. |
| first_indexed | 2024-03-07T03:20:59Z |
| format | Journal article |
| id | oxford-uuid:b767f3a0-072f-49c7-9dfa-bc85e30f05c5 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T03:20:59Z |
| publishDate | 2017 |
| publisher | Canadian Medical Association |
| record_format | dspace |
| spelling | oxford-uuid:b767f3a0-072f-49c7-9dfa-bc85e30f05c52022-03-27T04:48:25ZPersistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedulesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b767f3a0-072f-49c7-9dfa-bc85e30f05c5Symplectic Elements at OxfordCanadian Medical Association2017Sadarangani, MSell, TIro, MSnape, MVoysey, MFinn, AHeath, PBona, GEsposito, SDiez-Domingo, JPrymula, ROdueyungbo, AToneatto, DPollard, ABACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12–23 months, with a booster dose 12–24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12–24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12–24 months of age received a booster at 4 years of age. Vaccine-naive age-matched toddlers received 2 doses of 4CMenB. Human serum bactericidal antibody titres against reference strains H44/76, 5/99, NZ98/254 and M10713 were evaluated before and after innoculation with 4CMenB vaccine in 4-year-old children. RESULTS: Of 332 children in the study, 123 had previously received 4CMenB and 209 were vaccine-naive controls. Before the booster, the proportions of participants (previously vaccinated groups compared with controls) with hSBA titres of 1:5 or more were as follows: 9%–11% v. 1% (H44/76), 84%–100% v. 4% (5/99), 0%–18% v. 0% (NZ98/254) and 59%–60% v. 60% (M10713). After 1 dose of 4CMenB in previously immunized children, the proportions of participants achieving hSBA titres of 1:5 or more were 100% (H44/76 and 5/99), 70%–100% (NZ98/254) and 90%–100% (M10713). INTERPRETATION: We found that waning of hSBA titres by 4 years of age occurred after 2 doses of 4CMenB vaccine administered at 12–24 months, and doses at 12–24 months have a priming effect on the immune system. A booster may be necessary to maintain hSBA titres of 1:5 or more among those children with increased disease risk. |
| spellingShingle | Sadarangani, M Sell, T Iro, M Snape, M Voysey, M Finn, A Heath, P Bona, G Esposito, S Diez-Domingo, J Prymula, R Odueyungbo, A Toneatto, D Pollard, A Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules |
| title | Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules |
| title_full | Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules |
| title_fullStr | Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules |
| title_full_unstemmed | Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules |
| title_short | Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules |
| title_sort | persistence of immunity after vaccination with a capsular group b meningococcal vaccine in 3 different toddler schedules |
| work_keys_str_mv | AT sadaranganim persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT sellt persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT irom persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT snapem persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT voyseym persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT finna persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT heathp persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT bonag persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT espositos persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT diezdomingoj persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT prymular persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT odueyungboa persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT toneattod persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules AT pollarda persistenceofimmunityaftervaccinationwithacapsulargroupbmeningococcalvaccinein3differenttoddlerschedules |